Showing 3691-3700 of 8741 results for "".
- Study: Melanoma Referral Centers Worldwide Adopt Systemic Therapies, Reduce Lymph Node Removal Surgerieshttps://practicaldermatology.com/news/study-melanoma-referral-centers-worldwide-adopt-systemic-therapies-reduce-lymph-node-removal-surgeries/2461097/Lymph node removal surgery for patients with high-risk melanoma has become less common over the past few years while the use of targeted and immune therapies has risen rapidly at melanoma referral centers worldwide, an international group of researchers found. However, a large degree of
- Successful Topline Results Seen for Hallura's New BiOLinkMatrix HA Aesthetic Fillershttps://practicaldermatology.com/news/successful-topline-results-seen-for-halluras-new-biolinkmatrix-ha-aesthetic-fillers/2461096/Hallura Ltd’s hyaluronic acid (HA) dermal fillers with its proprietary BiOLinkMatrix platform performed well for lip enhancement, nasolabial folds correction. and cheek enhancement, according to topline results. The proprietary Bi
- Butt First, Endo Launches New Qwo Consumer Campaignhttps://practicaldermatology.com/news/butt-first-endo-launches-new-qwo-consumer-campaign/2461095/Endo International plc is kicking off more than 200 patient events across the United States as part of Butt First, a new direct-to-consumer awareness campaign about Qwo (collagenase clostridium histolyticum-aaes). Qwo received FDA approval in Jul
- Business News: Taro to Acquire Alchemee From Galdermahttps://practicaldermatology.com/news/business-news-taro-to-acquire-alchemee-from-galderma/2461087/Taro Pharmaceutical Industries Ltd. Is buying Alchemee, formerly The Proactiv Company, from Galderma. The acquisition is subject to customary closing conditions and any necessary regulatory approvals. Financial terms of the transaction have not been disclosed. "We are exc
- Study Establishes Optimal Drug Delivery Settings for Needle-free Jet Injectorshttps://practicaldermatology.com/news/study-establishes-optimal-drug-delivery-settings-for-needle-free-jet-injectors/2461085/Needle-free jet injectors have been used in dermatological practice for many years for the nearly pain-free transdermal drug delivery for indications such as hypertrophic scars, keloids, and warts, but predefined clinical endpoints that guide physicians to choose optimal device settings have not
- LEO Pharma A/S Appoints Brian Hilberdink New President of LEO Pharma Inc. United Stateshttps://practicaldermatology.com/news/leo-pharma-as-appoints-brian-hilberdink-new-president-of-leo-pharma-inc-united-states/2461084/LEO Pharma A/S appointed Brian Hilberdink as the new Executive Vice President and President of LEO Pharma Inc. in the United States, effective March 14, 2022. Brian Hilberdink joins LEO Pharma from Novo Nordisk, Inc., in the U.S. where he served as Senior Vice President of Sales.<
- Cyspera Launches New Three-Step System to Treat Hyperpigmentationhttps://practicaldermatology.com/news/cyspera-launches-new-three-step-system-to-treat-hyperpigmentation/2461083/Scientis is launching Cyspera Intensive System, a new three-product system designed to improve hyperpigmentation. Cysteamine inhibits several steps in the melanogenesis pathway while also working as antioxidant to protect against free radicals. The
- Study Identifies 29 New Acne Risk Geneshttps://practicaldermatology.com/news/study-identifies-29-new-acne-risk-genes/2461082/Researchers have identified 29 regions of the genome that influence acne. The new findings may open up new avenues of treatment and help clinicians identify individuals at high risk of severe acne. The research i
- PCA SKIN Looks to Space for Next Breakthrough in Skin Healthhttps://practicaldermatology.com/news/pca-skin-looks-to-space-for-next-breakthrough-in-skin-health/2461077/PCA SKIN plans to send the first-ever private sector skin health experiment to the International Space Station (ISS). The experiment, sponsored by the ISS National Lab, will explore the effects of microgravity on skin-related biomarkers in an effort to guide future product innovat
- Juvederm Volbella XC Scores FDA Nod for Undereye Hollowshttps://practicaldermatology.com/news/juvederm-volbella-xc-scores-fda-nod-for-undereye-hollows/2461071/The US Food and Drug Administration has given its nod to Allergan Aesthetics, Juvederm Volbella XC for improvement of infraorbital hollows in adults over the age of 21. Per FDA requirement for this new indication, Allergan Aesthetics is providing a product training